These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 21352561)

  • 1. Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial.
    Witzens-Harig M; Hensel M; Unterhalt M; Herfarth K
    BMC Cancer; 2011 Feb; 11():87. PubMed ID: 21352561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial.
    König L; Dreyling M; Dürig J; Engelhard M; Hohloch K; Viardot A; Witzens-Harig M; Kieser M; Klapper W; Pott C; Herfarth K
    Trials; 2019 Aug; 20(1):544. PubMed ID: 31470902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphoma.
    König L; Herfarth K; Hörner-Rieber J; Dietrich S; Wiegel T; Debus J; Viardot A
    Strahlenther Onkol; 2020 Aug; 196(8):705-714. PubMed ID: 32377821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.
    Ardeshna KM; Qian W; Smith P; Braganca N; Lowry L; Patrick P; Warden J; Stevens L; Pocock CF; Miall F; Cunningham D; Davies J; Jack A; Stephens R; Walewski J; Ferhanoglu B; Bradstock K; Linch DC
    Lancet Oncol; 2014 Apr; 15(4):424-35. PubMed ID: 24602760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701.
    Grant BW; Jung SH; Johnson JL; Kostakoglu L; Hsi E; Byrd JC; Jones J; Leonard JP; Martin SE; Cheson BD
    Cancer; 2013 Nov; 119(21):3797-804. PubMed ID: 23922187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial.
    Trotman J; Barrington SF; Belada D; Meignan M; MacEwan R; Owen C; Ptáčník V; Rosta A; Fingerle-Rowson GR; Zhu J; Nielsen T; Sahin D; Hiddemann W; Marcus RE; Davies A;
    Lancet Oncol; 2018 Nov; 19(11):1530-1542. PubMed ID: 30309758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG.
    Binkley MS; Brady JL; Hajj C; Chelius M; Chau K; Balogh A; Levis M; Filippi AR; Jones M; Ahmed S; MacManus M; Wirth A; Oguchi M; Vistisen AK; Andraos TY; Ng AK; Aleman BMP; Choi SH; Kirova YM; Hardy S; Reinartz G; Eich HT; Bratman SV; Constine LS; Suh CO; Dabaja B; El-Galaly TC; Hodgson DC; Ricardi U; Yahalom J; Mikhaeel NG; Hoppe RT
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):522-529. PubMed ID: 30858143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group.
    Feuring-Buske M; Kneba M; Unterhalt M; Engert A; Gramatzki M; Hiller E; Trümper L; Brugger W; Ostermann H; Atzpodien J; Hallek M; Aulitzky E; Hiddemann W
    Ann Hematol; 2000 Sep; 79(9):493-500. PubMed ID: 11043420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial.
    Pulsoni A; Ferrero S; Tosti ME; Luminari S; Dondi A; Cavallo F; Merli F; Liberati AM; Cenfra N; Renzi D; Zanni M; Boccomini C; Ferreri AJM; Rattotti S; Zilioli VR; Bolis SA; Bernuzzi P; Musuraca G; Gaidano G; Perrone T; Stelitano C; Tucci A; Corradini P; Bigliardi S; Re F; Cencini E; Mannarella C; Mannina D; Celli M; Tani M; Annechini G; Assanto GM; Grapulin L; Guarini A; Cavalli M; De Novi LA; Bomben R; Ciabatti E; Genuardi E; Drandi D; Della Starza I; Arcaini L; Ricardi U; Gattei V; Galimberti S; Ladetto M; Foà R; Del Giudice I
    Lancet Haematol; 2024 Jul; 11(7):e499-e509. PubMed ID: 38937025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study.
    Rajguru S; Kristinsdottir T; Eickhoff J; Peterson C; Meyer CM; Traynor AM; Kahl BS
    Clin Adv Hematol Oncol; 2014 Aug; 12(8):509-15. PubMed ID: 25356575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility and toxicity of concomitant radio/immunotherapy with MabThera (Rituximab®) for patients with non-Hodkin's Lymphoma: results of a prospective phase I/II study.
    Haidenberger A; Fromm-Haidenberger S; de Vries A; Popper BA; Steurer M; Skvortsova I; Kantner J; Gunsilius E; Lukas P
    Strahlenther Onkol; 2011 May; 187(5):300-5. PubMed ID: 21544528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma: Results of the MIR Study.
    Herfarth K; Borchmann P; Schnaidt S; Hohloch K; Budach V; Engelhard M; Viardot A; Engenhart-Cabillic R; Keller U; Reinartz G; Eich HT; Witzens-Harig M; Hess CF; Dörken B; Dürig J; Wiegel T; Hiddemann W; Hoster E; Pott C; Dreyling M
    Hemasphere; 2018 Dec; 2(6):e160. PubMed ID: 31723798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial.
    Watanabe T; Tobinai K; Wakabayashi M; Morishima Y; Kobayashi H; Kinoshita T; Suzuki T; Yamaguchi M; Ando K; Ogura M; Taniwaki M; Uike N; Yoshino T; Nawano S; Terauchi T; Hotta T; Nagai H; Tsukasaki K;
    Lancet Haematol; 2018 Nov; 5(11):e520-e531. PubMed ID: 30389034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab maintenance versus radioimmunotherapy consolidation in follicular lymphoma: which, when, and for whom?
    Forstpointner R; Dreyling M
    Curr Hematol Malig Rep; 2011 Dec; 6(4):207-15. PubMed ID: 21909660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary conjunctival follicular lymphoma treated with the anti-CD20 antibody rituximab and low-dose involved-field radiotherapy.
    Takahira M; Okumura H; Minato H; Urushisaki N; Sakurai M; Sugiyama K
    Jpn J Ophthalmol; 2007; 51(2):149-51. PubMed ID: 17401629
    [No Abstract]   [Full Text] [Related]  

  • 16. Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma.
    Cencini E; Puccini B; Rigacci L; Fabbri A; Kovalchuk S; Mannelli L; Benelli G; Carfagno T; Simontacchi G; Bocchia M; Bosi A
    Leuk Lymphoma; 2018 Jun; 59(6):1420-1426. PubMed ID: 28994343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiotherapy Compared to Other Strategies in the Treatment of Stage I/II Follicular Lymphoma: A Study of 404 Patients with a Median Follow-Up of 15 Years.
    Barzenje DA; Cvancarova Småstuen M; Liestøl K; Fosså A; Delabie J; Kolstad A; Holte H
    PLoS One; 2015; 10(7):e0131158. PubMed ID: 26147646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial.
    Ogura M; Sancho JM; Cho SG; Nakazawa H; Suzumiya J; Tumyan G; Kim JS; Lennard A; Mariz J; Ilyin N; Jurczak W; Lopez Martinez A; Samoilova O; Zhavrid E; Yañez Ruiz E; Trneny M; Popplewell L; Coiffier B; Buske C; Kim WS; Lee SJ; Lee SY; Bae YJ; Kwak LW
    Lancet Haematol; 2018 Nov; 5(11):e543-e553. PubMed ID: 30389036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.
    Fowler NH; Davis RE; Rawal S; Nastoupil L; Hagemeister FB; McLaughlin P; Kwak LW; Romaguera JE; Fanale MA; Fayad LE; Westin JR; Shah J; Orlowski RZ; Wang M; Turturro F; Oki Y; Claret LC; Feng L; Baladandayuthapani V; Muzzafar T; Tsai KY; Samaniego F; Neelapu SS
    Lancet Oncol; 2014 Nov; 15(12):1311-8. PubMed ID: 25439689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.
    Morschhauser F; Radford J; Van Hoof A; Vitolo U; Soubeyran P; Tilly H; Huijgens PC; Kolstad A; d'Amore F; Gonzalez Diaz M; Petrini M; Sebban C; Zinzani PL; van Oers MH; van Putten W; Bischof-Delaloye A; Rohatiner A; Salles G; Kuhlmann J; Hagenbeek A
    J Clin Oncol; 2008 Nov; 26(32):5156-64. PubMed ID: 18854568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.